CATALOGO DEI PRODOTTI DELLA RICERCA

PERTILE, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.148
EU - Europa 2.915
AS - Asia 1.710
SA - Sud America 229
Continente sconosciuto - Info sul continente non disponibili 83
AF - Africa 71
OC - Oceania 13
Totale 8.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.095
RU - Federazione Russa 950
SG - Singapore 672
IT - Italia 575
GB - Regno Unito 538
CN - Cina 481
BR - Brasile 193
DE - Germania 180
FR - Francia 166
HK - Hong Kong 161
VN - Vietnam 134
IE - Irlanda 126
SE - Svezia 121
FI - Finlandia 98
KR - Corea 62
BD - Bangladesh 50
IN - India 31
CA - Canada 29
UA - Ucraina 27
NL - Olanda 21
ES - Italia 20
JP - Giappone 19
BE - Belgio 18
PL - Polonia 18
TR - Turchia 15
ID - Indonesia 13
AU - Australia 12
EC - Ecuador 10
MX - Messico 10
NG - Nigeria 10
SA - Arabia Saudita 10
ZA - Sudafrica 10
IQ - Iraq 9
PT - Portogallo 9
TG - Togo 9
AR - Argentina 8
AT - Austria 8
EG - Egitto 7
IR - Iran 7
PK - Pakistan 7
BJ - Benin 6
CO - Colombia 6
CZ - Repubblica Ceca 6
MA - Marocco 6
TN - Tunisia 6
GR - Grecia 5
NO - Norvegia 5
CL - Cile 4
DO - Repubblica Dominicana 4
JO - Giordania 4
LT - Lituania 4
TW - Taiwan 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CH - Svizzera 3
DK - Danimarca 3
ET - Etiopia 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
PY - Paraguay 3
RO - Romania 3
SY - Repubblica araba siriana 3
VE - Venezuela 3
AZ - Azerbaigian 2
BH - Bahrain 2
BY - Bielorussia 2
CR - Costa Rica 2
IL - Israele 2
JM - Giamaica 2
LK - Sri Lanka 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
CG - Congo 1
DZ - Algeria 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LY - Libia 1
MR - Mauritania 1
MT - Malta 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 8.084
Salva come PNG Salva come JPEG
Città #
Southend 437
Singapore 364
Ashburn 340
San Jose 320
Dallas 319
Moscow 310
Chandler 308
Woodbridge 198
Verona 167
Ann Arbor 166
Jacksonville 164
Hong Kong 156
Council Bluffs 128
Dublin 118
The Dalles 78
Los Angeles 68
Beijing 66
Milan 59
Padova 56
New York 51
Princeton 46
Lawrence 44
Munich 43
Wilmington 42
Houston 40
Ho Chi Minh City 36
Helsinki 35
Nanjing 31
Hanoi 29
Shenyang 28
Buffalo 27
Tianjin 26
Jinan 25
São Paulo 23
Santa Clara 22
Frankfurt am Main 20
Boardman 18
Orem 18
Tokyo 18
Warsaw 18
Zhengzhou 16
Brussels 15
Guangzhou 15
Montreal 15
Rome 15
Columbus 14
Hebei 14
Lancaster 14
London 13
Phoenix 13
Sindelfingen 13
Taiyuan 13
Chennai 12
Redondo Beach 12
Stockholm 12
Haikou 11
Hangzhou 11
Seattle 11
Falkenstein 10
Ningbo 10
San Francisco 10
Chicago 9
Denver 9
Jakarta 9
Jiaxing 9
Lomé 9
Norwalk 9
Redmond 9
Roverbella 9
Taizhou 9
Abuja 8
Atlanta 8
Changsha 8
Manchester 8
Afragola 7
Ankara 7
Boston 7
Brooklyn 7
Da Nang 7
Dong Ket 7
Haiphong 7
Meda 7
Nanchang 7
Poplar 7
Riyadh 7
Amsterdam 6
Bari 6
Belluno 6
Belo Horizonte 6
Biên Hòa 6
Cotonou 6
Johannesburg 6
Lanzhou 6
Limena 6
Lonigo 6
Melbourne 6
Romola 6
Shanghai 6
Venice 6
Washington 6
Totale 5.011
Salva come PNG Salva come JPEG
Nome #
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysis 271
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 260
A Large Scale OLG Model for the Analysis of the Redistributive Effects of Policy Reforms 247
R&D and market size: who benefits from orphan drug regulation? 232
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 231
A stepped-wedge randomised controlled trial to assess efficacy and cost-effectiveness of a care-bundle to prevent falls in older hospitalised patients 223
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 219
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies 211
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919) 191
Investimenti pubblici, risorse scarse: il ruolo dei diversi metodi di supporto alle decisioni 189
Redistribution at the Local Level: The Case of Public Childcare in Italy 188
DRGs: the link between investment in technologies and appropriateness. WP Series University of Verona Department of Economics (ISSN 2036-2919), 31/2012 180
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919) 180
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 176
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry 168
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011 166
Job Sick Leave: Detecting Opportunistic Behavior 166
Public finance consolidation and fairness across living generations: the case of Italy. WP Series University of Verona Department of Economics (ISSN 2036-2919), 04/2012 164
Efficienza e sostenibilità dell’intervento pubblico 159
Improving access to medicines and promoting pharmaceutical innovation 158
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 157
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial 152
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012 150
A reply to "Who would benefit from average value-based pricing?" 147
Dynamic, incentive-compatible contracting for health services 144
The fiscal disadvantage of young italians: a new view on consolidation and fairness 143
The timing of adoption of positron emission tomography:a real options approach 142
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 141
Two-part payments for the reimbursement of investments in health technologies 139
Strategic Interaction in Pharmaceutical Price Regulation: With or Without U? 137
Optimal sequential sampling rules for the economic evaluation of health technologies 137
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy 137
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial 137
Investment in health technologies in a competitive model with real options 135
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" 135
The dynamics of pharmaceutical regulation and R&D investments 132
Which valued-based price when patients are heterogeneous? 132
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 130
Who should monitor job sick leave? 126
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 125
The impact of managed entry agreements on pharmaceutical prices 123
Technology adoption, quality and health care costs: a review of the literature 122
Optimal Decision Rules for HTA Under Uncertainty: a Wider, Dynamic Perspective 122
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 120
Pricing policies when patients are heterogeneous: a welfare analysis 120
R&D and market size: who benefits from orphan drug legislation? 119
Static and dynamic effciency of irreversible health care investments under alternative payment rules 114
L’equità intergenerazionale delle politiche di bilancio 108
Static and Dynamic Efficiency of Irreversible Health Care investments under Alternative Payment Rules 103
Public health interventions: evaluating the economic evaluations 102
Valutare l’efficienza dei servizi ospedalieri in Italia: il caso delle aziende ospedaliero-universitarie 93
Optimal Sequential Sampling with Delayed Observations and Unknown Variance 85
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 81
Totale 8.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.432
article - articoli 13.686
book - libri 0
conference - conferenze 421
curatela - curatele 514
other - altro 9.956
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.855
Totale 52.864
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022392 0 70 13 6 19 17 18 25 41 13 66 104
2022/2023804 60 96 72 122 76 194 7 53 84 12 24 4
2023/2024435 18 30 31 72 47 57 27 38 10 16 53 36
2024/20251.183 57 90 67 195 32 32 31 102 162 82 103 230
2025/20263.547 218 177 331 568 833 206 374 183 252 210 68 127
2026/2027173 82 91 0 0 0 0 0 0 0 0 0 0
Totale 8.169